A review of the pathophysiology of paroxysmal nocturnal hemoglobinuria

被引:0
作者
Holt, Matthew [1 ,2 ]
Newton, Darren J. [1 ,3 ]
Griffin, Morag [2 ]
Schmidt, Christoph Q. [4 ]
Kelly, Richard J. [2 ,3 ]
机构
[1] Univ Leeds, Div Haematol & Immunol, Leeds Inst Med Res St Jamess, Leeds, England
[2] Leeds Teaching Hosp NHS Trust, St Jamess Hosp, Dept Haematol, Leeds, England
[3] Natl Inst Hlth & Care Res NIHR, Leeds Biomed Res Ctr BRC NIHR203331, Leeds, England
[4] Univ Ulm, Inst Expt & Clin Pharmacol Toxicol & Pharmacol Nat, Med Ctr, Ulm, Germany
来源
ANNALS OF BLOOD | 2024年 / 9卷
关键词
Paroxysmal nocturnal hemoglobinuria (PNH); complement; pathophysiology; COMPLEMENT-FACTOR-H; PIG-A; ECULIZUMAB; CELLS; C5; INHIBITION; DEFICIENCY; MUTATIONS; HEMOLYSIS; VARIANTS;
D O I
10.21037/aob-24-25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, ultra-rare disease characterized by chronic intravascular hemolysis. It is classically caused by an acquired mutation in the phosphatidylinositol N-acetylglucosaminyltransferase subunit A ( PICA ) gene, though other gene mutations have been implicated. Whatever the initiating mutation, the result is a deficiency or loss of glycophosphatidylinositol (GPI) anchors from cell surfaces. These anchors are essential in binding proteins to cell membranes, with CD55 and CD59 being two important GPI-linked proteins lost in PNH. These ligands protect cells against complement; part of the innate immune system which promotes phagocytosis and lysis of invading pathogens. PNH cells appear to have a survival advantage over hematopoietic stem cells, often with the backdrop of bone marrow failure, leading to expansion of the PNH clone. Without the protection of CD55 and CD59, PNH red blood cells undergo complement-mediated hemolysis, causing a range of non-specific symptoms including anemia, fatigue, breathlessness and thrombosis. Untreated mortality can be high and before the advent of complement inhibitors treatment was limited to blood transfusions, anticoagulation, and bone marrow transplantation in a minority of patients. Complement inhibitors are now available which target components throughout the complement cascade and they have reduced PNH-associated morbidity and mortality. Treatment, however, carries the risk of infection, extravascular hemolysis and breakthrough hemolysis with some patients having better responses to others; perhaps in part due to polymorphisms of complement regulators. The aim of this review is to provide a thorough summary on the pathophysiology of not just the pathogenesis of PNH, but its clinical manifestations, treatment and their adverse effects, drawing on the impact of complement regulators, not covered in other review articles. Through reviewing the latest literature we have been able to identify areas where further ongoing research is required.
引用
收藏
页数:15
相关论文
共 78 条
  • [1] Apellis Pharmaceuticals Inc, 2021, EMPAVELITM (pegcetacoplan) injection, for subcutaneous use: US prescribing information Internet
  • [2] Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones
    Araten, DJ
    Bessler, M
    McKenzie, S
    Castro-Malaspina, H
    Childs, BH
    Boulad, F
    Karadimitris, A
    Notaro, R
    Luzzatto, L
    [J]. LEUKEMIA, 2002, 16 (11) : 2243 - 2248
  • [3] Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals
    Araten, DJ
    Nafa, K
    Pakdeesuwan, K
    Luzzatto, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (09) : 5209 - 5214
  • [4] Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes
    Berends, Evelien T. M.
    Gorham, Ronald D., Jr.
    Ruyken, Maartje
    Soppe, Jasper A.
    Orhan, Hatice
    Aerts, Piet C.
    de Haas, Carla J. C.
    Gros, Piet
    Rooijakkers, Suzan H. M.
    [J]. BMC BIOLOGY, 2015, 13
  • [5] PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) IS CAUSED BY SOMATIC MUTATIONS IN THE PIG-A GENE
    BESSLER, M
    MASON, PJ
    HILLMEN, P
    MIYATA, T
    YAMADA, N
    TAKEDA, J
    LUZZATTO, L
    KINOSHITA, T
    [J]. EMBO JOURNAL, 1994, 13 (01) : 110 - 117
  • [6] Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
    Bravo-Perez, Carlos
    Guarnera, Luca
    Williams, Nakisha D.
    Visconte, Valeria
    [J]. MEDICINA-LITHUANIA, 2023, 59 (09):
  • [7] Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    de latour, Regis Peffault
    Rottinghaus, Scott T.
    Roeth, Alexander
    Risitano, Antonio M.
    Weitz, Ilene C.
    Hillmen, Peter
    Maciejewski, Jaroslaw P.
    Szer, Jeff
    Lee, Jong Wook
    Kulasekararaj, Austin G.
    Volles, Lori
    Damokosh, Andrew I.
    Ortiz, Stephan
    Shafner, Lori
    Liu, Peng
    Hillc, Anita
    Schrezenmeier, Hubert
    [J]. HAEMATOLOGICA, 2021, 106 (01) : 230 - 237
  • [8] Inhibition of clotting factor XIII activity by nitric oxide
    Catani, MV
    Bernassola, F
    Rossi, A
    Melino, G
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 249 (01) : 275 - 278
  • [9] The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of paroxysmal nocturnal haemoglobinuria clones through cell metabolic reprogramming
    Chen, Yingying
    Liu, Hui
    Wang, Chaomeng
    Chen, Weixin
    Li, Liyan
    Wu, Junshu
    Wang, Guanrou
    Ling, Guang Sheng
    Fu, Rong
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (06) : 2468 - 2479
  • [10] Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
    Colden, Melissa A.
    Kumar, Sushant
    Munkhbileg, Bolormaa
    Babushok, Daria V.
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12